NIAB
  Skip Navigation Links  
  Digital India
 
Name:

Designation:

Areas of Specialization:

E-mail:

 
Dr. Bappaditya Dey

Scientist-E

Tuberculosis and Other Zoonotic Diseases of Livestock: Molecular Pathogenesis and Intervention Strategies.

bdey[at]niab[dot]org[dot]in

  
     
Education and training:

After graduating in Veterinary Sciences (B.V.Sc & A.H., 2002) from West Bengal University of Animal & Fishery Sciences, Kolkata Dr. Dey completed his masters in Animal Genetics and Breeding (MVSc, 2004) from CCS-Haryana Agricultural University, Hissar and subsequently, obtained his doctoral degree in Biochemistry (Ph.D, 2010) from University of Delhi, New Delhi. He continued his training in the same institute initially as a research associate and later as a Scientist-C until he moved to USA as a Post-doctoral Fellow at the Center for Tuberculosis Research, Johns Hopkins University, Baltimore (Feb. 2011-May. 2016). Subsequently, he worked as a Senior Research Scientist at the National Emerging Infectious Disease Laboratories (NEIDL), Boston University, Boston, USA (till Apr. 2017). Dr. Dey joined NIAB on 4th December, 2017.


Research experience and interests
Dr. Dey’s experience spans various aspects of research in Tuberculosis (TB) including, molecular basis of TB pathogenesis: host-pathogen interaction, immunology of TB and vaccine development and animal models of TB, TB latency and reactivation. He developed several genetically engineered recombinant vaccines, some of which imparted heightened protection among the experimental TB vaccines studied till date.

Dr. Dey’s group works on tuberculosis (TB) and other zoonotic bacterial diseases of livestock in the broad area of molecular pathogenesis, genetic diagnosis, engineered vaccines and therapies, especially- (a) identification of immunological and transcriptional biomarkers of susceptibility and/or resistance to TB in native and crossbred cattle, (b) development of inhibitors of a bacterial enzyme involved in biofilm formation and cell wall homeostasis to develop alternative antibacterial to limit antimicrobial resistance (AMR) and (C) development of engineered probiotics based novel prophylactic and therapeutic antimicrobial.


Selected awards, honors and fellowships:
  1. Ramanujan Fellowship (DST-SERB, Govt. of India, 2017)

  2. UGC-Faculty Recharge Program (UGC-FRP, Govt. of India) Assistant Professor (Selectee, Cycle IV, 2017)

  3. Post-doctoral fellowship: Johns Hopkins University, Baltimore, USA (2011-2016)

  4. Junior (2004-2005) and Senior Research Fellowship (2006-2009): Council of Scientific and Industrial Research (CSIR), Govt. of India

  5. Member, American Society for Microbiology, Society of Biological Chemist, Association of Microbiologists of India and Veterinary Council of India

Selected Publications
  1. Dey RJ*, Dey B*, Singh AK, Praharaj M, and Bishai WR. BCG overexpressing an endogenous STING agonist provides enhanced protection against pulmonary tuberculosis. Journal of Infectious Diseases. March 2019. doi: 10.1093/infdis/jiz116. *Joint first author.

  2. Dey RJ*, Dey B*, Zheng Y*, Cheung L, Zhou J , Sayre D, Kumar P, Guo H, Lamichhane G, Sintim HO, Bishai WR. Inhibition of innate immune cytosolic surveillance by a M. tuberculosis phosphodiesterase. Nature Chemical Biology. 2017 Feb. 13: 210-217. *Joint first author.

  3. Dey B, Dey RJ., Cheung SL, Pokkali S, Guo H, Lee JH and Bishai WR. A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis. Nature Medicine. 2015 Apr;21(4):401-6.

  4. Dey B, Bishai WR. Crosstalk between Mycobacterium tuberculosis and the host cell. Semin Immunol. Dec 2014; 26(6):486-496.

  5. Chauhan P, Jain R, Dey B, Tyagi AK. Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice. Sci Rep. 2013;3:1821.

  6. Jain R, Dey B, Tyagi AK. Development of the first oligonucleotide microarray for global gene expression profiling in guinea pigs: defining the transcription signature of infectious diseases. BMC Genomics. 2012 Oct 2;13:520.

  7. Dey B*, Jain R*, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK. A booster vaccine expressing a latency-associated antigen augments BCG induced immunity and confers enhanced protection against tuberculosis. PLoS One. 2011;6(8):e23360.

  8. Jain R*, Dey B*, Khera A, Srivastav P, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK. Over-expression of superoxide dismutase obliterates the protective effect of BCG against tuberculosis by modulating innate and adaptive immune responses. Vaccine. 2011 Oct 19;29(45):8118-25.

  9. Dey B*, Jain R*, Khera A, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK. Latency antigen α-crystallin based vaccination imparts a robust protection against TB by modulating the dynamics of pulmonary cytokines. PLoS One. 2011 Apr18;6(4):e18773.

  10. Dey B*, Jain R*, Khera A, Rao V, Dhar N, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK. Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs. Vaccine. 2009 Dec 10;28(1):63-70.

Detailed Profile





 
Mission & Vision

Mission: Development of sustainable and  globally competitive livestock industry through innovative technology.

Vision: To demonstrate excellence in promoting and commercializing leads in biotechnology and to produce globally competitive livestock products, pharmaceuticals and biologicals for animal health care.

Important Links


Preamble of the Constitution 

SAHAJ

NIAB SAIF

Instruments / Equipment (User Charges List) 

NIAB Bye Laws and RRs 

GST Details

Integrity Pledge

Digital NIAB

SPMS

Digital India Week

Annual Reports

Online Payment Link
 
  [ Log In ]  | RTI | DisclaimerContact | Copyrights © NIAB | Last updated date: 23-Apr-2024